News

Alvotech (ALVO): A Bull Case Theory
We came across a bullish thesis on Alvotech (ALVO) on M.V Cunha’s Substack. In this article, we will summarize the bulls’ ...
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Pharmabiz6h
EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea
EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea: Reykjavik, Iceland Tuesday, June 24, 2025, 17:00 Hrs [IST] Alvotech, a global biot ...
GlobalData on MSN1d
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.
Drug Store News7d
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar
Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...
NDTV Profit on MSN19d
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad ...
Business Wire1y
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in ...
Nasdaq3mon
Alvotech Expands Biosimilar Development Capabilities with Acquisition of Xbrane Biopharma R&D Operations - Nasdaq
Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...
Morningstar19d
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds ...
REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”) has completed a private placement of the equivalent of 7,500,000 shares in Swedish Depository ...
Nasdaq6mon
Alvotech to Join Nasdaq Biotechnology Index (NBI) Effective December 23, 2024
Alvotech, a global biotech company focused on developing biosimilar medicines, announced that its stock will be included in the Nasdaq Biotechnology Index (NBI) as part of the index's annual ...
Business Insider11mon
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® - Markets Insider
REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients ...
Morningstar3mon
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production - Morningstar
"Alvotech has a best-in-class biosimilars manufacturing site in Iceland, both for drug substance and drug products. At the same time, our strong in-house R&D capabilities have put Alvotech in a ...